Table 2.

Comparison of catheter-related bloodstream infections in Tego and control cohorts

	Control (n=6,493)	Tego (n=10,652)	P-value
IV antibiotic starts
At-risk time, patient-years	1,694	2,811
Events	2,225	3,308
Crude rate (95% CI), events per 100 patient-years	131 (126–137)	118 (114–122)
Crude IRR (95% CI)	1 (ref)	0.90 (0.85–0.95)	<0.001
Model 1: adjusted IRR (95% CI)	1 (ref)	0.92 (0.87–0.97)	0.002
Model 2: adjusted IRR (95% CI)	1 (ref)	0.92 (0.87–0.97)	0.002
IV antibiotic course (2+ doses within 21-day period)
At-risk time, patient-years	1,694	2,811
Events	1,730	2,499
Crude rate (95% CI), events per 100 patient-years	102 (97–107)	89 (85–92)
Crude IRR (95% CI)	1 (ref)	0.87 (0.82–0.93)	<0.001
Model 1: adjusted IRR (95% CI)	1 (ref)	0.89 (0.84–0.95)	<0.001
Model 2: adjusted IRR (95% CI)	1 (ref)	0.89 (0.84–0.95)	<0.001
Positive blood culture
At-risk time, patient-years	1,694	2,811
Events	526	828
Crude rate (95% CI), events per 100 patient-years	31 (28–34)	30 (28–32)
Crude IRR (95% CI)	1 (ref)	0.95 (0.85–1.06)	0.34
Model 1: adjusted IRR (95% CI)	1 (ref)	0.98 (0.88–1.09)	0.72
Model 2: adjusted IRR (95% CI)	1 (ref)	0.98 (0.88–1.09)	0.71

Notes: Model 1 adjusted for age, race, vintage, and etiology in end-stage renal disease; Model 2 adjusted for all variables (age, sex, race, vintage, primary cause of ESRD, diabetes, heart failure, ischemic disease, cerebrovascular disease, cardiac dysrythmia, COPD, liver disease, malignancy, and Charlson comorbidity index). Tego needlefree connector is manufactured by ICU Medical, Inc., San Clemente, CA, USA.

Abbreviations: CI, confidence interval; IRR, incidence-rate ratio; IV, intravenous; ref, reference.